论文部分内容阅读
目的:对肺癌合并糖尿病患者以长春瑞滨为主的联合化疗的疗效分析。方法:随机选取38例肺癌合并糖尿病患者,男20例,女18例,平均年龄(57.2±3.2)岁,肺癌病程平均(2.9±0.2)年;糖尿病程平均(4.3±0.7)年。进行长春瑞滨联合顺铂的NP化疗方案,观察疗效。结果:(1)1-4周期治疗有效率分别为27(71.1%)、20(57.9%)、15(42.1%)、8(21.1%)。(2)WBC减少18例(47.4%),呕吐22例(57.9%),便秘7例(18.4%),神经毒性反应12例(31.6%),治疗4周期后,对应不良反应患者分别为10例(26.3%),13例(34.2%),3例(7.9%),4例(10.5%)。(3)患者生存期4-6月、6-9月、9-12月、1年以上患者分别为19例、10例、7例、2例。中位生存时间(约6个月)明显低于单纯非小细胞癌的中位生存时间(10个月)。结论:长春瑞滨为主的联合化疗方案对初治肺癌合并糖尿病患者的疗效中,总有效率短期尚可,长期应用呈下降趋势。根据个体差异,对症治疗白细胞降低、便秘、呕吐等不良反应,可提高患者耐受性和生活质量。
OBJECTIVE: To analyze the curative effect of vinorelbine-based combination chemotherapy in patients with lung cancer complicated with diabetes mellitus. Methods: Thirty-eight male and 18 female patients with lung cancer were randomly selected. The average age was (57.2 ± 3.2) years. The average duration of lung cancer was (2.9 ± 0.2) years. The mean duration of diabetes was (4.3 ± 0.7) years. Vinorelbine combined with cisplatin NP chemotherapy, observe the effect. Results: (1) The effective rates of 1-4 cycles were 27 (71.1%), 20 (57.9%), 15 (42.1%) and 8 (21.1%), respectively. (2) WBC decreased in 18 cases (47.4%), vomiting in 22 cases (57.9%), constipation in 7 cases (18.4%) and neurotoxic reaction in 12 cases (31.6%). After 4 cycles of treatment, the corresponding adverse reactions were 10 Cases (26.3%), 13 cases (34.2%), 3 cases (7.9%), 4 cases (10.5%). (3) The patients’ survival period was 19 months, 10 cases, 7 cases and 2 cases in patients with 4-6 months, 6-9 months, 9-12 months and 1 year respectively. Median survival time (approximately 6 months) was significantly lower than that of simple non-small cell carcinoma (10 months). Conclusion: The combination of vinorelbine-based chemotherapy in newly diagnosed lung cancer patients with diabetes mellitus, the total effective rate may be short-term, long-term use of declining trend. According to individual differences, symptomatic treatment of leukopenia, constipation, vomiting and other adverse reactions, can improve patient tolerance and quality of life.